Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemporary Oncology/Współczesna Onkologia. 2018:68-72. doi:10.5114/wo.2018.73890.
APA
Mackiewicz, J., & Mackiewicz, A. (2018). BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemporary Oncology/Współczesna Onkologia, 68-72. https://doi.org/10.5114/wo.2018.73890
Chicago
Mackiewicz, Jacek, and Andrzej Mackiewicz. 2018. "BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients". Contemporary Oncology/Współczesna Onkologia: 68-72. doi:10.5114/wo.2018.73890.
Harvard
Mackiewicz, J., and Mackiewicz, A. (2018). BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemporary Oncology/Współczesna Onkologia, pp.68-72. https://doi.org/10.5114/wo.2018.73890
MLA
Mackiewicz, Jacek et al. "BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients." Contemporary Oncology/Współczesna Onkologia, 2018, pp. 68-72. doi:10.5114/wo.2018.73890.
Vancouver
Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemporary Oncology/Współczesna Onkologia. 2018:68-72. doi:10.5114/wo.2018.73890.
